The first two authors contributed equally to this work.
Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?
Article first published online: 22 NOV 2013
© 2013 John Wiley & Sons Ltd
Journal of Clinical Pharmacy and Therapeutics
Volume 39, Issue 1, pages 61–68, February 2014
How to Cite
Park, I.-W., Sheen, S. S., Yoon, D., Lee, S.-H., Shin, G.-T., Kim, H. and Park, R. W. (2014), Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?. Journal of Clinical Pharmacy and Therapeutics, 39: 61–68. doi: 10.1111/jcpt.12109
- Issue published online: 3 JAN 2014
- Article first published online: 22 NOV 2013
- Manuscript Accepted: 14 OCT 2013
- Manuscript Received: 11 OCT 2013
- National Research Foundation of Korea (NRF)
- Korea government (MSIP). Grant Numbers: 2010-0028631, A112022
- adverse effects;
- angiotensin receptor blockers;
What is known and objective
Angiotensin receptor blockers (ARBs) frequently induce hyperkalaemia in high-risk patients. Early detection of hyperkalaemia can reduce the subsequent harmful effects. This study was performed to examine the onset time of hyperkalaemia after ARB therapy.
We carried out a retrospective analysis to determine the onset time of hyperkalaemia (serum potassium >5·5 mm) among hospitalized patients newly starting ARB therapy between 2004 and 2012, in a tertiary teaching hospital. Predefined possible risk factors and concomitant medications were evaluated.
Results and discussion
During the 97-month study period, a total of 4267 hospitalized patients started ARBs as new drugs and 225 patients showed hyperkalaemia. A significantly increased risk of hyperkalaemia was detected among patients with a high baseline potassium [odds ratio (OR) 6·0] and those who took non-potassium-sparing diuretics (OR 2·2) or potassium supplements (OR 1·6). A high glomerular filtration rate (GFR) was associated with a lower risk of hyperkalaemia (OR 0·992). Fifty-two percentage of hyperkalaemic events occurred within the first week after initiation of ARB therapy. The highest frequency of hyperkalaemia occurred on the first day after initiation of ARBs. Hyperkalaemia occurred earlier in patients with a high baseline serum potassium level, reduced GFR, diabetes and in those without heart failure.
What is new and conclusion
Hyperkalaemia occurs most frequently at the beginning of ARB therapy in hospitalized patients. Monitoring of serum potassium and estimated GFR after initiation of ARBs should be started within a few days or not later than 1 week, especially in patients with risk factors.